Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031. The company has placed a strong emphasis on expanding its cancer drug portfolio and specialty medicines.
However, GSK's latest financial report comes amid a barrage of lawsuits, including a major investor lawsuit in the United States over alleged violations of federal securities laws.
